ATE507222T1 - 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren - Google Patents
1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatorenInfo
- Publication number
- ATE507222T1 ATE507222T1 AT06830045T AT06830045T ATE507222T1 AT E507222 T1 ATE507222 T1 AT E507222T1 AT 06830045 T AT06830045 T AT 06830045T AT 06830045 T AT06830045 T AT 06830045T AT E507222 T1 ATE507222 T1 AT E507222T1
- Authority
- AT
- Austria
- Prior art keywords
- thiomorpholinyl
- dioxo
- indolyl
- modulators
- methanone derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05111479 | 2005-11-30 | ||
PCT/EP2006/068649 WO2007062997A1 (en) | 2005-11-30 | 2006-11-20 | 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE507222T1 true ATE507222T1 (de) | 2011-05-15 |
Family
ID=37715997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06830045T ATE507222T1 (de) | 2005-11-30 | 2006-11-20 | 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren |
Country Status (17)
Country | Link |
---|---|
US (1) | US7538101B2 (de) |
EP (1) | EP1968967B1 (de) |
JP (1) | JP4879996B2 (de) |
KR (1) | KR101047204B1 (de) |
CN (1) | CN101316838B (de) |
AR (1) | AR057197A1 (de) |
AT (1) | ATE507222T1 (de) |
AU (1) | AU2006319232B2 (de) |
BR (1) | BRPI0619266A2 (de) |
CA (1) | CA2630307A1 (de) |
DE (1) | DE602006021626D1 (de) |
ES (1) | ES2362929T3 (de) |
NO (1) | NO20082214L (de) |
RU (1) | RU2412182C2 (de) |
TW (1) | TWI327144B (de) |
WO (1) | WO2007062997A1 (de) |
ZA (1) | ZA200804349B (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0619268A2 (pt) * | 2005-11-30 | 2011-09-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal |
ATE466007T1 (de) * | 2005-11-30 | 2010-05-15 | Hoffmann La Roche | 5-substituierte indol-2-carbonsäureamidderivate |
ES2627221T3 (es) | 2006-12-28 | 2017-07-27 | Rigel Pharmaceuticals, Inc. | Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso |
KR20100027231A (ko) | 2007-07-25 | 2010-03-10 | 에프. 호프만-라 로슈 아게 | 벤조퓨란- 및 벤조[b]티오펜-2-카복실산 아마이드 유도체 및 이의 히스타민 3 수용체 조절제로서의 용도 |
ES2552733T3 (es) * | 2007-11-16 | 2015-12-01 | Rigel Pharmaceuticals, Inc. | Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos |
CA2707047C (en) | 2007-12-12 | 2017-11-28 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
CN104016980B (zh) | 2008-04-23 | 2016-12-07 | 里格尔药品股份有限公司 | 用于治疗代谢障碍的甲酰胺化合物 |
US8785435B2 (en) * | 2011-10-20 | 2014-07-22 | Hoffmann-La Roche Inc. | Solid forms |
HUE030901T2 (en) * | 2012-08-23 | 2017-06-28 | Suven Life Sciences Ltd | Acrylamide compounds as histamine H3 receptor ligands |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
CA1270837A (en) * | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
US5246960A (en) * | 1984-12-21 | 1993-09-21 | Hoffmann-La Roche Inc. | Oxetanones |
CA1328881C (en) * | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
CA2035972C (en) * | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
US5338755A (en) * | 1990-07-31 | 1994-08-16 | Elf Sanofi | N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present |
US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
US6004996A (en) * | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
EP0978512A1 (de) * | 1998-07-29 | 2000-02-09 | Societe Civile Bioprojet | Aryloxy- (oder Arylthio)alkylamine ohne Imidazolring als Histamin-H3-Antagonisten und deren therapeutische Anwendung |
DK1105123T3 (da) | 1998-08-14 | 2004-08-09 | Hoffmann La Roche | Farmaceutiske præparater indeholdende lipase-inhibitorer og chitosan |
JP3774118B2 (ja) | 1998-08-14 | 2006-05-10 | エフ.ホフマン−ラ ロシュ アーゲー | リパーゼ阻害剤を含む製薬学的組成物 |
AU767830B2 (en) | 1999-03-29 | 2003-11-27 | F. Hoffmann-La Roche Ag | Glucokinase activators |
WO2002072548A2 (en) | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
EP1554260A1 (de) * | 2002-10-22 | 2005-07-20 | Glaxo Group Limited | Aryloxyalkylamine derivate als h3 rezeptor liganden |
AU2005254658B2 (en) * | 2004-06-21 | 2011-06-16 | F. Hoffmann-La Roche Ag | Indole derivatives as histamine receptor antagonists |
BRPI0619268A2 (pt) * | 2005-11-30 | 2011-09-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal |
-
2006
- 2006-11-20 WO PCT/EP2006/068649 patent/WO2007062997A1/en active Application Filing
- 2006-11-20 AT AT06830045T patent/ATE507222T1/de active
- 2006-11-20 AU AU2006319232A patent/AU2006319232B2/en not_active Ceased
- 2006-11-20 DE DE602006021626T patent/DE602006021626D1/de active Active
- 2006-11-20 EP EP06830045A patent/EP1968967B1/de not_active Not-in-force
- 2006-11-20 CN CN2006800448115A patent/CN101316838B/zh not_active Expired - Fee Related
- 2006-11-20 KR KR1020087015759A patent/KR101047204B1/ko not_active IP Right Cessation
- 2006-11-20 RU RU2008126389/04A patent/RU2412182C2/ru not_active IP Right Cessation
- 2006-11-20 BR BRPI0619266-1A patent/BRPI0619266A2/pt not_active IP Right Cessation
- 2006-11-20 JP JP2008542714A patent/JP4879996B2/ja not_active Expired - Fee Related
- 2006-11-20 CA CA002630307A patent/CA2630307A1/en not_active Abandoned
- 2006-11-20 ES ES06830045T patent/ES2362929T3/es active Active
- 2006-11-28 TW TW095143983A patent/TWI327144B/zh active
- 2006-11-28 AR ARP060105249A patent/AR057197A1/es not_active Application Discontinuation
- 2006-11-28 US US11/605,005 patent/US7538101B2/en not_active Expired - Fee Related
-
2008
- 2008-05-14 NO NO20082214A patent/NO20082214L/no not_active Application Discontinuation
- 2008-05-20 ZA ZA200804349A patent/ZA200804349B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
NO20082214L (no) | 2008-07-31 |
US20070123526A1 (en) | 2007-05-31 |
RU2008126389A (ru) | 2010-01-10 |
WO2007062997A1 (en) | 2007-06-07 |
JP2009517431A (ja) | 2009-04-30 |
ZA200804349B (en) | 2009-04-29 |
EP1968967B1 (de) | 2011-04-27 |
TW200804339A (en) | 2008-01-16 |
AU2006319232B2 (en) | 2012-09-13 |
RU2412182C2 (ru) | 2011-02-20 |
US7538101B2 (en) | 2009-05-26 |
BRPI0619266A2 (pt) | 2011-09-27 |
AR057197A1 (es) | 2007-11-21 |
CA2630307A1 (en) | 2007-06-07 |
KR20080076979A (ko) | 2008-08-20 |
JP4879996B2 (ja) | 2012-02-22 |
CN101316838B (zh) | 2013-01-30 |
KR101047204B1 (ko) | 2011-07-06 |
AU2006319232A1 (en) | 2007-06-07 |
CN101316838A (zh) | 2008-12-03 |
EP1968967A1 (de) | 2008-09-17 |
ES2362929T3 (es) | 2011-07-15 |
DE602006021626D1 (de) | 2011-06-09 |
TWI327144B (en) | 2010-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2019029I1 (no) | Guselkumab, se følgebrevet for nærmere forklaring | |
DE602006015297D1 (de) | 3-azetidincarbonsäure-derivate zur verwendung als immunsuppressiva | |
DE602004010791D1 (de) | 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren | |
CY2013047I2 (el) | Ενωσεις διαρυλυδαντοϊνης | |
BRPI0615433A2 (pt) | método de impressão | |
DK1928882T3 (da) | (s)-n-methylnaltrexon | |
NL1031385A1 (nl) | Gesubstitueerde sulfonylaminoarylmethylcyclopropaancarbonamideverbindingen. | |
DE602006005030D1 (de) | Phasenaustauschtinten | |
ATE507222T1 (de) | 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren | |
ATE443056T1 (de) | Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen | |
DE602006001805D1 (de) | Tintenzusammensetzung | |
DE602006007448D1 (de) | Tintenzusammensetzung | |
DE502006008852D1 (de) | Wechseleinrichtung | |
DE602006018216D1 (de) | Mannich Kondensationsprodukte zur Verwendung als Chelatbildner | |
DE602006014973D1 (de) | Neuartige cercosporamidderivate | |
DE602006007832D1 (de) | Benzotriazolderivate als cannabinoidrezeptorantagonisten | |
DE602007000679D1 (de) | Substituierte 4-phenylpiperidine zur verwendung als renininhibitoren | |
DE602006003967D1 (de) | Deckeleinrichtung | |
FR2888594B1 (fr) | Plaque alveolaire multiparois | |
DE602008003432D1 (de) | Substituierte furoä2,3-büpyridinderivate als cannabinoid-1-rezeptormodulatoren | |
FI20051205A0 (fi) | Jatkuvatoiminen retortti | |
ATE455770T1 (de) | N-alkynyl-2-heteroaryloxyalkylamide zur verwendung als fungizide | |
ES1061722Y (es) | Pavimento desmontable | |
FI20060991A0 (fi) | Oskillointisylinterin ohjaukseen tarkoitettu väline | |
FI20050534L (fi) | Menetelmä moniparametrisen tiedon analysoimiseksi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1968967 Country of ref document: EP |